Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Jasper Therapeutics, Inc.
Jasper Therapeutics develops antibody-based medicines for immune and inflammatory diseases, including mast cell disorders and stem cell transplant conditioning.
Jasper Therapeutics is a small clinical-stage biotech company working on a specific immune problem: mast cells, the cells that trigger allergic reactions and inflammation, and the conditioning step before a stem cell transplant. Its lead drug, briquilimab, is designed to block a receptor called c-Kit, which mast cells need to survive. Block that signal and the misbehaving mast cells die off, which could calm diseases where they run wild.
The most advanced use is chronic spontaneous urticaria, or hives that appear without a clear trigger and linger for months. Jasper reported that a mid-stage study of briquilimab in those patients met its goals, and it has been pushing toward later-stage testing. It is also studying the drug in chronic inducible urticaria and in asthma, where mast cells play a role in airway inflammation. The other side of the business is stem cell transplant conditioning. Before a transplant, patients usually get harsh chemotherapy or radiation to clear space in the bone marrow. Jasper wants briquilimab to do that job more gently by targeting the same c-Kit receptor, potentially making transplants safer for patients, including those with sickle cell disease and other blood disorders.
Like most clinical-stage biotechs, Jasper has no product on the market and earns no product revenue; it is funded by investors and burns cash on trials. That makes the science the whole story: if briquilimab works, it could be a franchise drug across several immune diseases. If trials stumble, the company has little else to fall back on. The stock is a bet on that single molecule.
Saved answer · last researched 14 Nov 2026